CELEX: 32017R2004
Language: en
Date: 2017-11-08 00:00:00
Title: Commission Implementing Regulation (EU) 2017/2004 of 8 November 2017 approving 2-methylisothiazol-3(2H)-one as an existing active substance for use in biocidal products of product-type 12 (Text with EEA relevance. )

9.11.2017   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               L 290/11
            
         COMMISSION IMPLEMENTING REGULATION (EU) 2017/2004
   of 8 November 2017
   approving 2-methylisothiazol-3(2H)-one as an existing active substance for use in biocidal products of product-type 12
   (Text with EEA relevance)
   THE EUROPEAN COMMISSION,
   Having regard to the Treaty on the Functioning of the European Union,
   Having regard to Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (1), and in particular the third subparagraph of Article 89(1) thereof,
   Whereas:
   
               (1)
            
            
               Commission Delegated Regulation (EU) No 1062/2014 (2) establishes a list of existing active substances to be evaluated for their possible approval for use in biocidal products. That list includes 2-methylisothiazol-3(2H)-one.
            
         
               (2)
            
            
               2-methylisothiazol-3(2H)-one has been evaluated for use in products of product-type 12, slimicides, as described in Annex V to Regulation (EU) No 528/2012.
            
         
               (3)
            
            
               Slovenia was designated as evaluating competent authority and submitted the assessment report together with its recommendations on 7 April 2016.
            
         
               (4)
            
            
               In accordance with Article 7(2) of Delegated Regulation (EU) No 1062/2014, the opinion of the European Chemicals Agency was formulated on 2 March 2017 by the Biocidal Products Committee, having regard to the conclusions of the evaluating competent authority.
            
         
               (5)
            
            
               According to that opinion, biocidal products of product-type 12 containing 2-methylisothiazol-3(2H)-one may be expected to satisfy the criteria of Article 19(1)(b) of Regulation (EU) No 528/2012, provided that certain specifications and conditions concerning their use are complied with.
            
         
               (6)
            
            
               It is therefore appropriate to approve 2-methylisothiazol-3(2H)-one for use in biocidal products of product-type 12, subject to compliance with certain specifications and conditions.
            
         
               (7)
            
            
               Since 2-methylisothiazol-3(2H)-one meets the criteria for classification as skin sensitiser sub-category 1A as specified in Annex I to Regulation (EC) No 1272/2008 of the European Parliament and of the Council (3), treated articles treated with or incorporating 2-methylisothiazol-3(2H)-one should be appropriately labelled when placed on the market.
            
         
               (8)
            
            
               A reasonable period should be allowed to elapse before an active substance is approved in order to permit interested parties to take the preparatory measures necessary to meet the new requirements.
            
         
               (9)
            
            
               The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Biocidal Products,
            
         HAS ADOPTED THIS REGULATION:
   Article 1
   2-methylisothiazol-3(2H)-one is approved as an active substance for use in biocidal products of product-type 12, subject to the specifications and conditions set out in the Annex.
   Article 2
   This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
   
      This Regulation shall be binding in its entirety and directly applicable in all Member States.
      Done at Brussels, 8 November 2017.
      
         
            For the Commission
         
         
            The President
         
         Jean-Claude JUNCKER
      
   
   
      (1)  OJ L 167, 27.6.2012, p. 1.
   
      (2)  Commission Delegated Regulation (EU) No 1062/2014 of 4 August 2014 on the work programme for the systematic examination of all existing active substances contained in biocidal products referred to in Regulation (EU) No 528/2012 of the European Parliament and of the Council (OJ L 294, 10.10.2014, p. 1).
   
      (3)  Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (OJ L 353, 31.12.2008, p. 1).
   
      ANNEX
      
                  Common Name
               
               
                  IUPAC Name
                  Identification Numbers
               
               
                  Minimum degree of purity of the active substance (1)
                  
               
               
                  Date of approval
               
               
                  Expiry date of approval
               
               
                  Product type
               
               
                  Specific conditions
               
            
                  2-methylisothiazol-3(2H)-one
               
               
                  IUPAC Name:
                  2-methylisothiazol-3(2H)-one
                  EC No: 220-239-6
                  CAS No: 2682-20-4
               
               
                  950 g/kg
               
               
                  1 April 2019
               
               
                  31 March 2029
               
               
                  12
               
               
                  The authorisations of biocidal products are subject to the following conditions:
                  
                              1.
                           
                           
                              The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any use covered by an application for authorisation, but not addressed in the Union-level risk assessment of the active substance.
                           
                        
                              2.
                           
                           
                              In view of the risks identified for the uses assessed, the product assessment shall pay particular attention to:
                              
                                          (a)
                                       
                                       
                                          industrial and professional users;
                                       
                                    
                                          (b)
                                       
                                       
                                          surface water and sewage treatment plants.
                                       
                                    
                        The placing on the market of treated articles is subject to the following condition:
                  The person responsible for the placing on the market of a treated article treated with or incorporating 2-methylisothiazol-3(2H)-one shall ensure that the label of that treated article provides the information listed in the second subparagraph of Article 58(3) of Regulation (EU) No 528/2012.
               
            
         (1)  The purity indicated in this column was the minimum degree of purity of the active substance evaluated. The active substance in the product placed on the market can be of equal or different purity if it has been proven to be technically equivalent to the evaluated active substance.